WO2014205237A3 - Compositions and methods for use of high molecular weight hyaluronic acid for cancer therapy - Google Patents

Compositions and methods for use of high molecular weight hyaluronic acid for cancer therapy Download PDF

Info

Publication number
WO2014205237A3
WO2014205237A3 PCT/US2014/043213 US2014043213W WO2014205237A3 WO 2014205237 A3 WO2014205237 A3 WO 2014205237A3 US 2014043213 W US2014043213 W US 2014043213W WO 2014205237 A3 WO2014205237 A3 WO 2014205237A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hyaluronic acid
molecular weight
high molecular
compositions
Prior art date
Application number
PCT/US2014/043213
Other languages
French (fr)
Other versions
WO2014205237A2 (en
Inventor
Vera Gorbunova
Andrei Seluanov
Original Assignee
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rochester filed Critical University Of Rochester
Publication of WO2014205237A2 publication Critical patent/WO2014205237A2/en
Publication of WO2014205237A3 publication Critical patent/WO2014205237A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01212—Hyaluronan synthase (2.4.1.212)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The disclosure provides compositions and methods for treating or preventing cancer in a subject in need thereof. Specifically, the disclosure provides a composition comprising high molecular weight hyaluronic acid (HMW-HA) or an isolated nucleic acid encoding mole-rat hyaluronic acid synthase 2 (HAS2), and methods for increasing the level of HMW-HA in a subject, thereby treating or preventing cancer.
PCT/US2014/043213 2013-06-19 2014-06-19 Compositions and methods for use of high molecular weight hyaluronic acid for cancer therapy WO2014205237A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361956952P 2013-06-19 2013-06-19
US61/956,952 2013-06-19

Publications (2)

Publication Number Publication Date
WO2014205237A2 WO2014205237A2 (en) 2014-12-24
WO2014205237A3 true WO2014205237A3 (en) 2015-03-19

Family

ID=52105513

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/043213 WO2014205237A2 (en) 2013-06-19 2014-06-19 Compositions and methods for use of high molecular weight hyaluronic acid for cancer therapy

Country Status (1)

Country Link
WO (1) WO2014205237A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3769788A1 (en) * 2016-01-13 2021-01-27 Genzyme Corporation Recombinant aav vectors expressing osteoprotective genes, including has2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178342A1 (en) * 2000-07-14 2006-08-10 Tracey Brown Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
US20130131009A1 (en) * 2010-03-24 2013-05-23 University Of Rochester Compositions Comprising High Molecular Weight Hyaluronic Acid and Methods For Producing Same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178342A1 (en) * 2000-07-14 2006-08-10 Tracey Brown Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
US20130131009A1 (en) * 2010-03-24 2013-05-23 University Of Rochester Compositions Comprising High Molecular Weight Hyaluronic Acid and Methods For Producing Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BURDICK ET AL.: "Hyaluronic Acid Hydrogels for Biomedical Applications.", ADV MATER., vol. 23, no. 12, 2011, pages H41 - 56, XP055011775, DOI: doi:10.1002/adma.201003963 *
PETRELLA ET AL.: "LONG-TERM EFFICACY AND SAFETY OF A COMBINED HYALURONIC ACID IN OSTEOARTHRITIS OF THE KNEE.", MICROSOFT POWERPOINT, PV LONG TERM POSTER, EULAR., 2010, Retrieved from the Internet <URL:http://www.renehavis.de/sites/defautt/files/studie_rv_long_term_poster_eular_2010-2.pdf> *

Also Published As

Publication number Publication date
WO2014205237A2 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
ES2670983T3 (en) Methods and compositions related to CRISPR with rRNA guiding
EP4400584A3 (en) Guide rna with chemical modifications
AU2015329974A8 (en) GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
MX2016002544A (en) Compounds useful as immunomodulators.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2015085318A3 (en) Targeted adaptive vaccines
MX2015011898A (en) Pyrazolo compounds and uses thereof.
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
WO2014035140A3 (en) Compounds and compositions for modulating histone methyltransferase activity
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
WO2014143855A3 (en) Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
MX2016008096A (en) Surface treatment of particles and their use.
EP3328800A4 (en) Scale inhibiting polymer compositions, mixtures, and methods of using the same
EP3106478A4 (en) Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
MA40460A (en) Lysosomal targeting and uses thereof
WO2012097093A3 (en) Novel wnt compositions and therapeutic uses of such compositions
IL241823B (en) C. novyi containing compositions and uses thereof in treating solid tumors
EP3220895A4 (en) The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3044365A4 (en) High molecular weight and high cationic chargeglyoxalatedpolyacrylamide copolymers, and their methods of manufacture and use
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EP3090025A4 (en) Dye, filler made therefrom, compositions including the filler, and method of determining degree of cure of such compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14813988

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14813988

Country of ref document: EP

Kind code of ref document: A2